Adma Biologics (ADMA) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
ADMA Biologics Reports Second Quarter 2015 Results
August 11, 2015 4:38 PM EDTRAMSEY, N.J., Aug. 11, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the second quarter ended June 30, 2015, in addition to providing a corporate update and anticipated milestones for 2015.
"The last several months have been a transformational period for ADMA and its stakeholders. During this time, we submitted our Biologics License Application (BLA) seeking marketing approval for RI-002 to the U.S. Food and Drug... More
